| Literature DB >> 28336035 |
Perry J Evangelista1, Michael W Aversano2, Emmanuel Koli3, Lorraine Hutzler2, Ifeoma Inneh2, Joseph Bosco2, Richard Iorio2.
Abstract
Tranexamic acid (TXA) is used to reduce blood loss in orthopedic total joint arthroplasty (TJA). This study evaluates the effectiveness of TXA in reducing transfusions and hospital cost in TJA. Participants undergoing elective TJA were stratified into 2 cohorts: those not receiving and those receiving intravenous TXA. TXA decreased total hip arthroplasty (THA) transfusions from 22.7% to 11.9%, and total knee arthroplasty (TKA) from 19.4% to 7.0%. The average direct hospital cost reduction for THA and TKA was $3083 and $2582, respectively. Implementation of a TJA TXA protocol significantly reduced transfusions in a safe and cost-effective manner.Entities:
Keywords: Blood transfusion; Cost comparative analysis; Primary joint arthroplasty; Tranexamic acid
Mesh：
Substances：
Year: 2017 PMID： 28336035 DOI： 10.1016/j.ocl.2016.12.001
Source DB: PubMed Journal: Orthop Clin North Am ISSN： 0030-5898 Impact factor: 2.472